EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy and Safety of Switching From Intravenous to Subcutaneous Vedolizumab in Japanese Patients With Ulcerative Colitis: A Study Focusing on Injection‐Site Reactions

Makoto Furuya, Kiichiro Yoza, Takeshi Yonezawa, Ken Takeuchi iD

JGH Open · 2026-04 · 10 (4)

DOI: 10.1002/jgh3.70407 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JGH Open, online erschienen am 21.04.2026. Verfasst von Makoto Furuya und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology IBD Center, Tsujinaka Hospital Kashiwanoha Chiba Japan. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Aims The subcutaneous (SC) formulation of vedolizumab is available as an alternative to the intravenous (IV) formulation in patients with ulcerative colitis (UC). However, data from Asian patients are limited, and the clinical course of injection‐site reactions (ISRs) remains unclear. This study evaluated the efficacy and safety of switching from IV to SC vedolizumab in Japanese patients with UC, focusing on ISRs.

Methods

This retrospective study included patients who switched from IV to SC vedolizumab. The primary outcomes were the incidence and clinical course of ISRs. The secondary outcomes included adverse events other than ISRs, disease activity, remission rates, and treatment persistence.

Results

In total, 48 patients were included. The median fecal calprotectin levels remained stable from baseline to 12 months after switching (46.0 vs. 46.0 μg/g), with the fecal calprotectin remission rate remaining stable (41/45, 91% vs. 39/45, 87%). The persistence rate of SC vedolizumab was 98%, and the persistence rate without additional therapy was 94%. ISRs occurred in 29 patients (60%), most frequently within 3–6 months, with a median duration of 4 months. More than half of ISRs improved or resolved by 12 months, and only 11 patients (23%) experienced persistent ISRs. No adverse events other than ISRs were considered likely or probably related to SC vedolizumab.

Conclusions

In Asian patients with UC, disease activity was maintained after switching from IV to SC vedolizumab. Although ISRs were common after switching, most were self‐limiting. Therefore, switching back to IV formulation solely for ISR management should be cautiously considered.

Schlagwörter

Stichwörter der Autor:innen

injection‐site reactionsreal‐world datasubcutaneous injectionulcerative colitisvedolizumab

Autor:innen und Institutionen

  • Department of Gastroenterology IBD Center, Tsujinaka Hospital Kashiwanoha Chiba Japan.
  • Department of Gastroenterology Graduate School of Medicine, Chiba University Chiba Japan.

ORCID-Profile: Ken Takeuchi

Zitieren

APA

Furuya, M., Yoza, K., Yonezawa, T., & Takeuchi, K. (2026). Efficacy and Safety of Switching From Intravenous to Subcutaneous Vedolizumab in Japanese Patients With Ulcerative Colitis: A Study Focusing on Injection‐Site Reactions. JGH Open, 10(4). https://doi.org/10.1002/jgh3.70407

Vancouver

Furuya M, Yoza K, Yonezawa T, Takeuchi K. Efficacy and Safety of Switching From Intravenous to Subcutaneous Vedolizumab in Japanese Patients With Ulcerative Colitis: A Study Focusing on Injection‐Site Reactions. JGH Open. 2026;10(4). doi:10.1002/jgh3.70407

BibTeX
@article{Furuya2026,
  author = {Furuya, Makoto and Yoza, Kiichiro and Yonezawa, Takeshi and Takeuchi, Ken},
  title = {Efficacy and Safety of Switching From Intravenous to Subcutaneous Vedolizumab in Japanese Patients With Ulcerative Colitis: A Study Focusing on Injection‐Site Reactions},
  journal = {JGH Open},
  year = {2026},
  volume = {10},
  number = {4},
  doi = {10.1002/jgh3.70407}
}
Kostenlos starten →